| Citation: |
LIAO Jinhao, GAO Yuting, WANG Xiang, WANG Zhiwei, XU Qiang, ZHAO Yuxing, CHI Yue, MAO Jiangfeng, YANG Hongbo. Multiple Liver Metastases in Malignant Insulinoma: A Case Report[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 968-972. DOI: 10.12290/xhyxzz.2024-0208
|
Malignant insulinoma is a kind of rare and challenging neuroendocrine tumor. It is often accompanied by distant metastasis, among which liver metastasis is most common, and the prognosis is often non-promising. In this paper, we report a case of multiple liver metastases from malignant insulinoma. The patient, a 70-year-old male, was admitted to the hospital due to "episodic consciousness disorder for more than four months." Blood glucose monitoring revealed recurrent hypoglycemia in the early morning, after meals, and at night. Pancreatic perfusion CT and dynamic enhanced MRI of the liver revealed a mass in the uncinate process of the pancreatic head and multiple liver metastases. Percutaneous liver biopsy confirmed the diagnosis of insulinoma. After multidisciplinary discussions, hepatic artery embolization and radiofrequency ablation were performed in stages, in combination with everolimus treatment. Thereafter, the enhanced CT demonstrated that some liver metastases shrank. The patient had regular meals, and the blood sugar gradually increased and remained normal thereafter. This article discusses this case's clinical characteristics and multidisciplinary collaborative diagnosis and treatment, aiming to provide experience for the comprehensive clinical diagnosis and treatment of malignant insulinoma patients.
| [1] |
Kittah N E, Vella A. Management of endocrine disease: pathogenesis and management of hypoglycemia[J]. Eur J Endocrinol, 2017, 177(1): R37-R47. DOI: 10.1530/EJE-16-1062
|
| [2] |
Zhu L, Xue H D, Sun H, et al. Insulinoma detection with MDCT: is there a role for whole-pancreas perfusion?[J]. AJR Am J Roentgenol, 2017, 208(2): 306-314. DOI: 10.2214/AJR.16.16351
|
| [3] |
Zhu L, Xue H D, Sun Z Y, et al. Prospective comparison of biphasic contrast-enhanced CT, volume perfusion CT, and 3 Tesla MRI with diffusion-weighted imaging for insulinoma detection[J]. J Magn Reson Imaging, 2017, 46(6): 1648-1655. DOI: 10.1002/jmri.25709
|
| [4] |
Brandi M L, Agarwal S K, Perrier N D, et al. Multiple endocrine neoplasia type 1: latest insights[J]. Endocr Rev, 2021, 42(2): 133-170. DOI: 10.1210/endrev/bnaa031
|
| [5] |
吴文铭, 陈洁, 白春梅, 等. 中国胰腺神经内分泌肿瘤诊疗指南(2020)[J]. 中华消化外科杂志, 2021, 20(6): 579-599. DOI: 10.3760/cma.j.cn115610-20210520-00224
Wu W M, Chen J, Bai C M, et al. The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020)[J]. Chin J Dig Surg, 2021, 20(6): 579-599. DOI: 10.3760/cma.j.cn115610-20210520-00224
|
| [6] |
Baudin E, Caron P, Lombard-Bohas C, et al. Malignant insulinoma: recommendations for characterisation and treatment[J]. Ann Endocrinol (Paris), 2013, 74(5/6): 523-533.
|
| [7] |
Yu R, Nissen N N, Hendifar A, et al. A clinicopathological study of malignant insulinoma in a contemporary series[J]. Pancreas, 2017, 46(1): 48-56. DOI: 10.1097/MPA.0000000000000718
|
| [8] |
Sada A, Glasgow A E, Vella A, et al. Malignant insulinoma: a rare form of neuroendocrine tumor[J]. World J Surg, 2020, 44(7): 2288-2294. DOI: 10.1007/s00268-020-05445-x
|
| [9] |
Kurakawa K I, Okada A, Manaka K, et al. Clinical characteristics and incidences of benign and malignant insulinoma using a national inpatient database in Japan[J]. J Clin Endocrinol Metab, 2021, 106(12): 3477-3486.
|
| [10] |
Frilling A, Li J, Malamutmann E, et al. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease[J]. Br J Surg, 2009, 96(2): 175-184. DOI: 10.1002/bjs.6468
|
| [11] |
Caplin M E, Pavel M, Phan A T, et al. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study[J]. Endocrine, 2021, 71(2): 502-513. DOI: 10.1007/s12020-020-02475-2
|
| [12] |
Vogl T J, Naguib N N N, Zangos S, et al. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation[J]. Eur J Radiol, 2009, 72(3): 517-528. DOI: 10.1016/j.ejrad.2008.08.008
|
| [13] |
Mohan H, Nicholson P, Winter D C, et al. Radiofrequency ablation for neuroendocrine liver metastases: a systematic review[J]. J Vasc Interv Radiol, 2015, 26(7): 935-942. e1. DOI: 10.1016/j.jvir.2014.12.009
|
| [14] |
Engelman E S, Leon-Ferre R, Naraev B G, et al. Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution[J]. Pancreas, 2014, 43(2): 219-225. DOI: 10.1097/MPA.0000000000000030
|
| [15] |
Rinke A, Krug S. Neuroendocrine tumours-medical therapy: biological[J]. Best Pract Res Clin Endocrinol Metab, 2016, 30(1): 79-91. DOI: 10.1016/j.beem.2015.09.004
|
| [16] |
Brighi N, Lamberti G, Maggio I, et al. Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. a retrospective observational study[J]. Dig Liver Dis, 2019, 51(5): 689-694. DOI: 10.1016/j.dld.2018.09.013
|
| [17] |
Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2020, 31(7): 844-860. DOI: 10.1016/j.annonc.2020.03.304
|
| [18] |
Jin K Z, Xu J, Chen J, et al. Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: a consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET)[J]. Int J Oncol, 2016, 49(5): 1991-2000. DOI: 10.3892/ijo.2016.3711
|
| [19] |
Burns L, Naimi B, Ronan M, et al. Report of a novel molecular profile in malignant insulinoma[J]. J Clin Med, 2023, 12(4): 1280. DOI: 10.3390/jcm12041280
|
| [20] |
Bösch F, Brüwer K, Altendorf-Hofmann A, et al. Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia[J]. Endocr Relat Cancer, 2019, 26(3): 293-301. DOI: 10.1530/ERC-18-0494
|
| [1] | WANG Qi, CHEN Miao. Advances in Immunotargeted Therapy for Warm Autoimmune Hemolytic Anemia[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(2): 423-430. DOI: 10.12290/xhyxzz.2024-0668 |
| [2] | WANG Jun, MENG Juan. Targeted Therapy for Rheumatoid Arthritis in the New Era[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1): 19-27. DOI: 10.12290/xhyxzz.2024-0842 |
| [3] | QIN Jing, ZHU Qingli. Early Efficacy Assessment of Targeted Therapy for Crohn's Disease by Ultrasound[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(1): 130-134. DOI: 10.12290/xhyxzz.2023-0306 |
| [4] | LIN Meijia, ZENG Yeting, WANG Xinrui, HUANG Xiongfei. Research Progress of Isocitrate Dehydrogenase Gene Mutation Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 346-352. DOI: 10.12290/xhyxzz.2022-0176 |
| [5] | LI Guo-yu, HE Ming. Research Progress of Targeted Therapy at Rare Targets for Non-small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 268-274. DOI: 10.3969/j.issn.1674-9081.2020.00.019 |
| [6] | Hua-xia YANG, Feng-chun ZHANG. New Biologic Targets for Systemic Lupus Erythematosus: Hope and Challenge[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 241-246. DOI: 10.3969/j.issn.1674-9081.20200091 |
| [7] | Ying XU, Yan LIN, Chang-jun WANG, Jia-lin ZHAO, Qiang SUN. Whether Elderly Patients with Her-2 Positive Breast Cancer but Without Heart Disease Should Receive Targeted Therapy?[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(4): 414-418. DOI: 10.3969/j.issn.1674-9081.2019.04.020 |
| [8] | Xi-nan SHENG, Jun GUO. Current Status and Prospects of the Treatment of Advanced Renal Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(2): 148-151. DOI: 10.3969/j.issn.1674-9081.2019.02.012 |
| [9] | Su-jie ZHANG, Hua-qi YIN, Xiong-jun YE, Tao XU. Role of Musashi-2 in the Occurrence and Development and as the Diagnostic and Therapeutic Target of Malignant Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(4-5): 289-293. DOI: 10.3969/j.issn.1674-9081.2017.05.018 |
| [10] | Lei TANG, Hua-dan XUE, Zheng-yu JIN. Radiological Evaluation of the Response of Abdominal Tumors to Targeted Therapy: Current Status and Prospect[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(2-3): 82-89. DOI: 10.3969/j.issn.1674-9081.2017.03.001 |
| 1. |
冯彦飞，杨小杰，强建红，高彩霞，汤喜红. 系统性红斑狼疮患者血清miR125b-5-p水平与Th1/Th2细胞、Th17/Treg细胞失衡的相关性. 检验医学与临床. 2025(02): 227-231 .
| |
| 2. |
官春晓，王雨群，孟珊，马秀芬，高文风，王晓东，苏玉华. 基于Toll样受体/核因子κB信号通路探讨miRNA-146a在系统性红斑狼疮中的作用. 潍坊医学院学报. 2024(02): 87-90 .
| |
| 3. |
牛爱云，李燕，胡炳彦. 中重度系统性红斑狼疮患者的泰它西普规范化治疗效果观察. 中国标准化. 2024(12): 249-252 .
| |
| 4. |
杜福亮，赵秀姻. 系统性红斑狼疮患者血清补体及免疫球蛋白的表达水平及其临床意义. 医药前沿. 2024(19): 71-73 .
| |
| 5. |
刘晓薇，窦存瑞. 新型冠状病毒感染与自身免疫性疾病关系的研究进展. 医药前沿. 2024(31): 32-34 .
| |
| 6. |
谢雪，何子梦. 系统性红斑狼疮患者的营养评估与干预. 名医. 2024(15): 42-44 .
|
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Submit
Review
Office
Email Alert
RSS
DownLoad: